In brief: Ambri; QIC; Solbec; IDT
Monday, 13 December, 2004
Sydney-based biosensor developer Ambri (ASX:ABI) has made chief financial officer Jeff Carter redundant, citing a drive to redirect resources towards its biosensor platform. Ambri's current financial controller, Phillip Camilleri, will assume the role of company secretary, and take over responsibility of all financial matters.
The Queensland Investment Corporation (QIC) has become a substantial shareholder in Melbourne's Prima Biomed (ASX:PPR), with a holding of 5.6 per cent.
Perth-based biotech Solbec Pharmaceuticals (ASX:SBP) has signed up the Adelaide-based Institute of Drug Technology (ASX:IDT) to manufacture its Coramsine compound to FDA standard for Phase II clinical trials. The compound is currently being tested as a therapeutic for cancer and psoriasis.
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
Life expectancy gains are slowing, study finds
Life expectancy at birth in the world's longest-living populations has increased by an...
Towards safer epilepsy treatment for pregnant women
New research conducted in organoids is expected to provide pregnant women with epilepsy safer...